AstraZeneca announced a planned investment of $50 billion in the United States by 2030, aimed at expanding its manufacturing and research and development activities. The investment supports the company's goal of reaching $80 billion in revenue by 2030, with half of that total expected to be generated in the U.S.
Editorial use only Contact your sales representative for commercial and promotional uses.License this clip
More footage filed by NurPhoto videographers.